All In Biotech

Drug Trial Radar · NCT02467335

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jan 29, 2015

Primary completion

Oct 3, 2015

Study completion Oct 3, 2015

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jun 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

  • BMS-663068Drug

    BMS-663068

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The effects of hepatic impairment on the single-dose peak plasma concentration Cmax of BMS-626529 (metabolite).Time frame: 5 days
  2. The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (INF) of BMS-626529 (metabolite).Time frame: 5 days
  3. The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (0-T) of BMS-626529 (metabolite).Time frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Hamilton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.